Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H16N3O6S.Na |
Molecular Weight | 329.305 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C([O-])=O
InChI
InChIKey=QWXDICNEPRTOLR-GEMLJDPKSA-M
InChI=1S/C10H17N3O6S.Na/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16;/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19);/q;+1/p-1/t5-,6-;/m0./s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Glutathione (GSH, also called as reduced glutathione) is a tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes such as, glutathione reductase, glutathione peroxidases, peroxiredoxins. Glutathione S-transferases catalyse the conjugation of GSH via a sulfhydryl group to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. As a part of homeopathic product, glutathione is used for temporary relief of symptoms related to Free Radical Toxicity including tingling in hands and feet, mood changes, frequent colds, poor digestion, fatigue, and constipation. In addition, for temporary relief of pain in the back from urinating, constant urging and frequent urination, kidneys sensitive to pressure, and pain from back extending down the thigh. Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. In phase II of the clinical trial was investigated whether administration of either dose of glutathione, as a nasal spray, improves PD symptoms over time in a population of individuals with Parkinson's disease (PD). In addition in phase II of clinical trial was shown, that reduced glutathione, an ingredient of RayGel™, has been helpful in decreasing some radiation therapy side effects to the skin. Reduced glutathione plays a vital role in both making DNA and cell repair. Cystic fibrosis (CF) is the most common inherited disease among the Caucasian population with considerable morbidity and reduced life expectancy. Glutathione (GSH) represents the first-line defence of the lung against oxidative stress-induced cell injury. Therapeutic approaches with inhaled GSH could improve the reduced lung antioxidant capacity in order to counterbalance the oxidant stress linked to the chronic airway inflammation and bacterial infection.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Glutathione S-transferases Sources: https://www.ncbi.nlm.nih.gov/pubmed/4436301 |
|||
Target ID: P00390 Gene ID: 2936.0 Gene Symbol: GSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
|||
Target ID: Glutathione peroxidases Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Contribution of the mesangium to elastic strength and anchorage of the glomerular capillary tuft. | 2001 |
|
Assays for mitogen-activated protein kinase (MAPK) subtypes and MAPK activating protein kinase-2 (MAPKAP K-2) using a common cell lysate. | 2001 |
|
Perturbation of the pore of the cystic fibrosis transmembrane conductance regulator (CFTR) inhibits its atpase activity. | 2001 Apr 13 |
|
A rice functional transcriptional activator, RISBZ1, responsible for endosperm-specific expression of storage protein genes through GCN4 motif. | 2001 Apr 27 |
|
Localization of the C-terminus of rat glutathione S-transferase A1-1: crystal structure of mutants W21F and W21F/F220Y. | 2001 Feb 1 |
|
Nitrogen monoxide (no) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells. | 2001 Feb 16 |
|
The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. | 2001 Feb 2 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of substrate binding to the active site of glutathione transferases. | 2001 Feb 23 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases. | 2001 Feb 23 |
|
Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. | 2001 Feb 9 |
|
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. | 2001 Jan |
|
Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. | 2001 Jan |
|
The activity of NF-kappaB in Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke is dependent on thioredoxin. | 2001 Jan |
|
Ochratoxin A-induced tumor formation: is there a role of reactive ochratoxin A metabolites? | 2001 Jan |
|
Dual effects of nitric oxide in functional and regressing rat corpus luteum. | 2001 Jan |
|
Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. | 2001 Jan |
|
Major changes in human ocular UV protection with age. | 2001 Jan |
|
Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. | 2001 Jan |
|
Oxidative stress and antioxidant defenses in goldfish Carassius auratus during anoxia and reoxygenation. | 2001 Jan |
|
Overcoming drug resistance in ovarian carcinoma. | 2001 Jan |
|
Cellular thiols and reactive oxygen species in drug-induced apoptosis. | 2001 Jan |
|
Glutathione attenuates coronary constriction to acetylcholine in patients with coronary spastic angina. | 2001 Jan |
|
Glutathione in disease. | 2001 Jan |
|
Homocysteine and thiol metabolites in vitamin B12 deficiency. | 2001 Jan |
|
Genomic organization and putative promoters of highly conserved glutathione S-transferases originating by alternative splicing in Anopheles dirus. | 2001 Jan |
|
The intracellular oxidation of 2',7'-dichlorofluorescin in murine T lymphocytes. | 2001 Jan 1 |
|
Thiols can either enhance or suppress DNA damage induction by catecholestrogens. | 2001 Jan 1 |
|
Superoxide radical-initiated apoptotic signalling pathway in selenite-treated HepG(2) cells: mitochondria serve as the main target. | 2001 Jan 1 |
|
Catalase in astroglia-rich primary cultures from rat brain: immunocytochemical localization and inactivation during the disposal of hydrogen peroxide. | 2001 Jan 12 |
|
Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. | 2001 Jan 12 |
|
The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. | 2001 Jan 26 |
|
Reconstitution of pterin-free inducible nitric-oxide synthase. | 2001 Jan 5 |
|
2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. | 2001 Jan 5 |
|
Preventive effect of diethyldithiocarbamate on selenite-induced opacity in cultured rat lenses. | 2001 Jan-Feb |
|
Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain. | 2001 Mar |
|
Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. | 2001 Mar 2 |
|
gamma -glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response. | 2001 Mar 23 |
|
A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. | 2001 Mar 30 |
|
Structural properties and mechanisms that govern association of C kinase adapter 1 with protein kinase C3 and the cell periphery. | 2001 Mar 30 |
|
Silencing mediator for retinoid and thyroid hormone receptors interacts with octamer transcription factor-1 and acts as a transcriptional repressor. | 2001 Mar 30 |
|
Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. | 2001 Mar 30 |
|
CyaG, a novel cyanobacterial adenylyl cyclase and a possible ancestor of mammalian guanylyl cyclases. | 2001 Mar 30 |
|
Functional characterization of and cooperation between the double-stranded RNA-binding motifs of the protein kinase PKR. | 2001 Mar 30 |
|
A direct inhibitory role for the Rab3-specific effector, Noc2, in Ca2+-regulated exocytosis in neuroendocrine cells. | 2001 Mar 30 |
|
Phosphorylation of tau is regulated by PKN. | 2001 Mar 30 |
|
Assembly of scaffold-mediated complexes containing Cdc42p, the exchange factor Cdc24p, and the effector Cla4p required for cell cycle-regulated phosphorylation of Cdc24p. | 2001 Mar 9 |
|
Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor. | 2001 Mar 9 |
|
Protein kinase C activation modulates alpha-calmodulin kinase II binding to NR2A subunit of N-methyl-D-aspartate receptor complex. | 2001 Mar 9 |
|
Zinc release from the CH2C6 zinc finger domain of FILAMENTOUS FLOWER protein from Arabidopsis thaliana induces self-assembly. | 2001 Mar 9 |
|
Expression-independent consumption of substrates in cell-free expression system from Escherichia coli. | 2001 Nov 17 |
Patents
Sample Use Guides
For temporary relief of symptoms related to Free Radical Toxicity: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
pain in the back from urinating: 10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.
Breast Cancer: RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
Cystic Fibrosis: Inhaled Reduced Glutathione 10 mg/kg, twice daily, 12 months
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
H0X6UKX533
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
100000078214
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
SUB76116
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
ALTERNATIVE | |||
|
SUB13991MIG
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
92043348
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
DTXSID90955757
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
34212-83-4
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
20167-21-9
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY | |||
|
251-884-1
Created by
admin on Sat Dec 16 03:01:49 GMT 2023 , Edited by admin on Sat Dec 16 03:01:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD